̽»¨¾«Ñ¡

Mark G.J. de Boer is a professor in Infectious Diseases at Leiden University Medical Center, The Netherlands.
At present he relocated to Stockholm as visiting scholar at Karolinska Institute, in the RG of Pontus Naucler.

Mark is the past president (per 07-02-'25) of the Dutch Working Party on Antibiotic Policy (Dutch acronym: SWAB). The SWAB is responsible for the national guidance on- and implementation of prudent antimicrobial therapy and antimicrobial stewardship; but also has an important role in the monitoring of antimicrobial consumption and antimicrobial resistance in the Dutch hospitals.

He has acquired and participated in grant-funded research (including RCTs) on the topics of antimicrobial therapy, prosthetic joint infection, antimicrobial resistance and antimicrobial stewardship. As senior researcher, he has performed many studies on understanding and improving antimicrobial treatment and stewardship. In 2017 he was appointed to develop and chair a new national eduction program in infectious diseases obligated for residents in internal medicine (COIG). Furthermore he has contributed to national guideline development (sepsis, diverticulitis, handling antibiotic allergy (chair)). From the start of the COVID-19 pandemic Mark de Boer has chaired the Dutch national advice on the ̽»¨¾«Ñ¡ therapy of COVID-19 for hospitalized patients from february 2020 onwards.

Next to his ̽»¨¾«Ñ¡ specialty, Mark de Boer is qualified as a clinical epidemiologist. In 2019 he was elected a Fellow of the Infectious Disease Society of America (FIDSA). . In 2024 Mark was elected into the executive committee of ESGAP, ESCMIDs studygroup for antimicrobial policies and antimicrobial stewardship, where he has the function of honorary secretary. 

Antimicrobial Resistance: Antimicrobial Stewardship, Infected prosthetic materials, Fungal Infections, Epidemiology, Antimicrobial Pharmacotherapy.